U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns
As the U.S. locks up supplies to make Pfizer's COVID-19 vaccine, Serum Institute of India and WHO are raising flags about global supply bottlenecks and raw materials shortfalls, Bloomberg reports. The supply disruption comes after the Biden administration tapped the Defense Production Act to increase deliveries of Pfizer's shot in the U.S.